Merck MRK, known as MSD outside the United States and Canada, confirmed
today that interim data from the company's Phase IB expansion study (PN 001)
evaluating the efficacy and safety of *MK-3475 in patients with refractory
non-small cell lung cancer (NSCLC) is scheduled for presentation at the 15th
World Conference on Lung Cancer on Oct. 29 at 4:15 p.m., (1:15 a.m. EDT), in
Sydney, Australia.
An abstract (# 2416) published today summarized preliminary findings from 38
patients with NSCLC treated with MK-3475. Data from additional patients and an
analysis of tumor PD-L1 expression is scheduled to be presented by Dr. Edward
Garon, Director of Thoracic Oncology, Jonsson Comprehensive Cancer Center,
University of California, Los Angeles, during the conference.
“These early data in lung cancer patients were the basis for Merck's decision
to rapidly advance MK-3475 into a Phase II/III clinical trial in NSCLC,” said
Dr. Eric H. Rubin, vice president, Oncology, Merck Research Laboratories. “We
look forward to further discussion of the data following its presentation at
the conference.”
The published abstract describes early data for 38 patients with NSCLC treated
with MK-3475 as a single agent dosed at 10mg/kg every three weeks. The
preliminary objective response rate (confirmed and unconfirmed) was 24 percent
as measured using investigator-assessed immune related response criteria
(irRC) and 21 percent, (confirmed and unconfirmed), by RECIST v1.1. The most
common treatment-related adverse events observed were fatigue, rash, and
pruritus (16 percent each); diarrhea grade 1 or 2 occurred in 13 percent of
patients. One case of a drug-related grade 3 pulmonary edema was reported.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in